ClinicalTrials.Veeva

Menu

High-frequency vs. Low-frequency vs. Sham DMPFC-rTMS for Major Depression

University Health Network, Toronto logo

University Health Network, Toronto

Status

Unknown

Conditions

Depression

Treatments

Device: High-frequency rTMS
Device: Sham rTMS
Device: Low-frequency rTMS

Study type

Interventional

Funder types

Other

Identifiers

NCT02702154
15-9276-A

Details and patient eligibility

About

This trial will compare the efficacy and tolerability of 20 Hz vs. 1 Hz vs. sham repetitive transcranial magnetic stimulation targeting the dorsomedial prefrontal cortex, delivered twice daily over 15 days, in patients with a diagnosis of major depressive disorder. The trial will include structural and functional MRI, EEG, and behavioral measures obtained before, during, and after treatment.

Enrollment

120 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria (Patient):

  • Voluntary and competent to consent to treatment
  • MINI confirmed diagnosis of MDD
  • Outpatient
  • Between the ages of 18-65
  • Failed to achieve a clinical response to at least one pharmacotherapy or behavioral treatment in the current episode.
  • Have had no increase or initiation of any psychotropic medication in the last 4 weeks prior to screening
  • Must adhere to study assessment and intervention schedule.
  • Pass the TMS Safety Screening Questionnaire.

Exclusion Criteria (Patient):

  • Have a concomitant major unstable medical illness, cardiac pacemaker or implanted medical pump
  • Have active suicidal intent
  • Are pregnant
  • Have a lifetime MINI diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform, delusional disorder, or current psychotic symptoms have a MINI diagnosis of obsessive-compulsive disorder, post-traumatic stress disorder (current or within the last year), anxiety disorder (generalized anxiety disorder, social anxiety disorder, panic disorder), or dysthymia assessed by a study investigator to be primary and causing greater impairment than MDD
  • Have received rTMS for any previous indication due to the potential compromise of subject blinding.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

120 participants in 3 patient groups

High-frequency rTMS
Experimental group
Description:
20 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, twice daily, 5 days per week for 3 weeks
Treatment:
Device: High-frequency rTMS
Low-frequency rTMS
Experimental group
Description:
1 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, twice daily, 5 days per week for 3 weeks
Treatment:
Device: Low-frequency rTMS
Sham rTMS
Sham Comparator group
Description:
Sham repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, twice daily, 5 days per week for 3 weeks
Treatment:
Device: Sham rTMS

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems